Ares Life Sciences Articles
Ares Life Sciences aims to take full control of Stallergenes, having already bought Wendel’s 46% stake in the firm
18 November 2010
Showing 1-3 of 3 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
